Evidence map›Paper›PMID 42592468›Full record

ArticleActa pharmaceutica Sinica. B2026

Novel noscapine derivative induces AML differentiation by dual-engaging DHODH and mitochondrial lipids to trigger a metabolic-epigenetic-transcriptional cascade.

Shuting Shen, Defeng Li, Youping Zhang, Shiwei Li, Lei Li, Wenhao Shen, Yujie Ma, Wenhao Zhang, Rong Tao, Wei Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shuting ShenShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Defeng LiShanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Youping ZhangDepartment of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Shiwei LiShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Lei LiShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Wenhao ShenShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Yujie MaDepartment of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Wenhao ZhangDepartment of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Rong TaoDepartment of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Wei WangDepartment of Pharmacology and Toxicology and BIO5 Institute, University of Arizona, Tucson, AZ 85721, USA.
Biao JiangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Fang BaiShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
Chuanxu LiuDepartment of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yongqiang ZhangShanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Qianqian YinShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a heterogeneous and devastating hematologic malignancy characterized by differentiation blockage and immature progenitor accumulation, positioning differentiation therapy as a promising therapeutic strategy. However, clinical success is largely confined to acute promyelocytic leukemia (APL) and isocitrate dehydrogenase (IDH)-mutated AML, leaving most AML subtypes with unmet needs. Herein, novel noscapine derivative ES428 is discovered that induces AML differentiation and exhibits potent anti-AML efficacy across diverse AML cell lines, primary patient samples, as well as cell line- and patient-derived xenograft models. Target deconvolution with combinatorial strategies identifies dihydroorotate dehydrogenase (DHODH), a rate-limiting enzyme in

Indexed as

Acute myeloid leukemiaDe novo pyrimidine synthesisDifferentiation therapyEP300/CREBBPNoscapine derivativeNovel DHODH inhibitorProtein‒lipid dual engagementTranscriptional reprogramming

Identifiers

PMID42592468
PMCPMC13464086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.